Merck reports fiscal Q2 2026 results: revenue $16.61B, up 5% from a year earlier

Merck filed a Form 8-K with the SEC on Aug 4, 2026, 6:47 AM ET, reporting an event dated Aug 4, 2026. It covers Item 2.02 (Results of Operations and Financial Condition); Item 9.01 (Financial Statements and Exhibits). The results cover fiscal Q2 2026 (quarter ended Jun 30, 2026); figures below are from the company's XBRL financial data filed with the SEC.

• Revenue: $16.61B (+5.1% from $15.81B a year earlier)
• Net income: −$1.33B (vs $4.43B a year earlier)
• Diluted EPS: $-0.54 (vs $1.76 a year earlier)
• Form 8-K accepted by EDGAR Aug 4, 2026, 6:47 AM ET
• Accession number 0001104659-26-090045

SEC filing 8-K · accession 0001104659-26-090045 · sec.gov ↗